Last reviewed · How we verify
FAK Inhibitor GSK2256098
FAK Inhibitor GSK2256098 is a Small molecule drug developed by Alliance for Clinical Trials in Oncology. It is currently in Phase 2 development.
At a glance
| Generic name | FAK Inhibitor GSK2256098 |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas (PHASE2)
- A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer (PHASE2)
- A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors (PHASE1)
- Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients (PHASE1)
- Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers (PHASE1)
- Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FAK Inhibitor GSK2256098 CI brief — competitive landscape report
- FAK Inhibitor GSK2256098 updates RSS · CI watch RSS
- Alliance for Clinical Trials in Oncology portfolio CI
Frequently asked questions about FAK Inhibitor GSK2256098
What is FAK Inhibitor GSK2256098?
FAK Inhibitor GSK2256098 is a Small molecule drug developed by Alliance for Clinical Trials in Oncology.
Who makes FAK Inhibitor GSK2256098?
FAK Inhibitor GSK2256098 is developed by Alliance for Clinical Trials in Oncology (see full Alliance for Clinical Trials in Oncology pipeline at /company/alliance-for-clinical-trials-in-oncology).
What development phase is FAK Inhibitor GSK2256098 in?
FAK Inhibitor GSK2256098 is in Phase 2.